http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 02 Jun 2026 16:16:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BIOCRYST+PHARMACEUTICALS++For%3A+May+29++Filed+by%3A+Milne+Jill+C./26591924.html si-local-file:///var/storage/secattach/20260602/26591924.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BIOCRYST+PHARMACEUTICALS++For%3A+May+29++Filed+by%3A+Milne+Jill+C./26591924.html Tue, 02 Jun 2026 16:16:00 -0400 BCRX O.00165123 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BIOCRYST+PHARMACEUTICALS++For%3A+May+29++Filed+by%3A+Milne+Jill+C./26591924.html si-local-file:///var/storage/secattach/20260602/26591924.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BIOCRYST+PHARMACEUTICALS++For%3A+May+29++Filed+by%3A+Milne+Jill+C./26591924.html Tue, 02 Jun 2026 16:16:00 -0400 BCRX O.00165123 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BIOCRYST+PHARMACEUTICALS++For%3A+May+29++Filed+by%3A+Stonehouse+Jon+P/26591815.html si-local-file:///var/storage/secattach/20260602/26591815.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BIOCRYST+PHARMACEUTICALS++For%3A+May+29++Filed+by%3A+Stonehouse+Jon+P/26591815.html Tue, 02 Jun 2026 16:14:00 -0400 BCRX O.00165123 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BIOCRYST+PHARMACEUTICALS++For%3A+May+29++Filed+by%3A+Stonehouse+Jon+P/26591815.html si-local-file:///var/storage/secattach/20260602/26591815.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BIOCRYST+PHARMACEUTICALS++For%3A+May+29++Filed+by%3A+Stonehouse+Jon+P/26591815.html Tue, 02 Jun 2026 16:14:00 -0400 BCRX O.00165123 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BIOCRYST+PHARMACEUTICALS++For%3A+May+29++Filed+by%3A+McKee+Amy+E/26591745.html si-local-file:///var/storage/secattach/20260602/26591745.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BIOCRYST+PHARMACEUTICALS++For%3A+May+29++Filed+by%3A+McKee+Amy+E/26591745.html Tue, 02 Jun 2026 16:11:00 -0400 BCRX O.00165123 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BIOCRYST+PHARMACEUTICALS++For%3A+May+29++Filed+by%3A+McKee+Amy+E/26591745.html si-local-file:///var/storage/secattach/20260602/26591745.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BIOCRYST+PHARMACEUTICALS++For%3A+May+29++Filed+by%3A+McKee+Amy+E/26591745.html Tue, 02 Jun 2026 16:11:00 -0400 BCRX O.00165123 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BIOCRYST+PHARMACEUTICALS++For%3A+May+29++Filed+by%3A+MILANO+VINCENT/26591677.html si-local-file:///var/storage/secattach/20260602/26591677.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BIOCRYST+PHARMACEUTICALS++For%3A+May+29++Filed+by%3A+MILANO+VINCENT/26591677.html Tue, 02 Jun 2026 16:09:00 -0400 BCRX O.00165123 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BIOCRYST+PHARMACEUTICALS++For%3A+May+29++Filed+by%3A+MILANO+VINCENT/26591677.html si-local-file:///var/storage/secattach/20260602/26591677.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BIOCRYST+PHARMACEUTICALS++For%3A+May+29++Filed+by%3A+MILANO+VINCENT/26591677.html Tue, 02 Jun 2026 16:09:00 -0400 BCRX O.00165123 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BIOCRYST+PHARMACEUTICALS++For%3A+May+29++Filed+by%3A+Frank+Steven/26591599.html si-local-file:///var/storage/secattach/20260602/26591599.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BIOCRYST+PHARMACEUTICALS++For%3A+May+29++Filed+by%3A+Frank+Steven/26591599.html Tue, 02 Jun 2026 16:07:00 -0400 BCRX O.00165123 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BIOCRYST+PHARMACEUTICALS++For%3A+May+29++Filed+by%3A+Frank+Steven/26591599.html si-local-file:///var/storage/secattach/20260602/26591599.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BIOCRYST+PHARMACEUTICALS++For%3A+May+29++Filed+by%3A+Frank+Steven/26591599.html Tue, 02 Jun 2026 16:07:00 -0400 BCRX O.00165123 http://www.streetinsider.com/Press+Releases/BioCryst+to+Present+New+HAE+Data+from+ORLADEYO%C2%AE+%28berotralstat%29+and+Navenibart+at+the+2026+European+Academy+of+Allergy+and+Clinical+Immunology+Annual+Meeting/26553317.html <p align="justify">RESEARCH TRIANGLE PARK, N.C., May 27, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=rWjnYBZ0NEv6PV8MV_OqzZbCyf-t1cv1dpK0IGNVXzVwSpJslKzI8yNpkg-ckrtUAVApCIMobIE0oXi1Y6IBIWWY2uGejegxXq-da3CVED5HycqD-IvNIIZ1DQm04P09" rel="nofollow" target="_blank">BioCryst Pharmaceuticals, Inc.</a> (Nasdaq: BCRX) today announced that the company will present seven abstracts from its hereditary angioedema (HAE) portfolio at the Annual Meeting of the European Academy of Allergy and Clinical Immunology (EAACI) taking place in Istanbul, Turkey, from June 12-15, 2026.</p> <p align="justify">Data include six abstracts featuring new clinical trial and real-world outcomes with ORLADEYO® (berotralstat), the first and only targeted oral prophylactic therapy for patients with HAE aged 2 and older, and one abstract featuring clinical trial outcomes http://www.streetinsider.com/Press+Releases/BioCryst+to+Present+New+HAE+Data+from+ORLADEYO%C2%AE+%28berotralstat%29+and+Navenibart+at+the+2026+European+Academy+of+Allergy+and+Clinical+Immunology+Annual+Meeting/26553317.html Wed, 27 May 2026 07:00:00 -0400 A.50201579 BCRX O.00165123 O.12524441 http://www.streetinsider.com/Press+Releases/BioCryst+to+Present+New+HAE+Data+from+ORLADEYO%C2%AE+%28berotralstat%29+and+Navenibart+at+the+2026+European+Academy+of+Allergy+and+Clinical+Immunology+Annual+Meeting/26553317.html <p align="justify">RESEARCH TRIANGLE PARK, N.C., May 27, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=rWjnYBZ0NEv6PV8MV_OqzZbCyf-t1cv1dpK0IGNVXzVwSpJslKzI8yNpkg-ckrtUAVApCIMobIE0oXi1Y6IBIWWY2uGejegxXq-da3CVED5HycqD-IvNIIZ1DQm04P09" rel="nofollow" target="_blank">BioCryst Pharmaceuticals, Inc.</a> (Nasdaq: BCRX) today announced that the company will present seven abstracts from its hereditary angioedema (HAE) portfolio at the Annual Meeting of the European Academy of Allergy and Clinical Immunology (EAACI) taking place in Istanbul, Turkey, from June 12-15, 2026.</p> <p align="justify">Data include six abstracts featuring new clinical trial and real-world outcomes with ORLADEYO® (berotralstat), the first and only targeted oral prophylactic therapy for patients with HAE aged 2 and older, and one abstract featuring clinical trial outcomes http://www.streetinsider.com/Press+Releases/BioCryst+to+Present+New+HAE+Data+from+ORLADEYO%C2%AE+%28berotralstat%29+and+Navenibart+at+the+2026+European+Academy+of+Allergy+and+Clinical+Immunology+Annual+Meeting/26553317.html Wed, 27 May 2026 07:00:00 -0400 A.50201579 BCRX O.00165123 O.12524441 http://www.streetinsider.com/Press+Releases/BioCryst+to+Present+New+HAE+Data+from+ORLADEYO%C2%AE+%28berotralstat%29+and+Navenibart+at+the+2026+European+Academy+of+Allergy+and+Clinical+Immunology+Annual+Meeting/26553317.html <p align="justify">RESEARCH TRIANGLE PARK, N.C., May 27, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=rWjnYBZ0NEv6PV8MV_OqzZbCyf-t1cv1dpK0IGNVXzVwSpJslKzI8yNpkg-ckrtUAVApCIMobIE0oXi1Y6IBIWWY2uGejegxXq-da3CVED5HycqD-IvNIIZ1DQm04P09" rel="nofollow" target="_blank">BioCryst Pharmaceuticals, Inc.</a> (Nasdaq: BCRX) today announced that the company will present seven abstracts from its hereditary angioedema (HAE) portfolio at the Annual Meeting of the European Academy of Allergy and Clinical Immunology (EAACI) taking place in Istanbul, Turkey, from June 12-15, 2026.</p> <p align="justify">Data include six abstracts featuring new clinical trial and real-world outcomes with ORLADEYO® (berotralstat), the first and only targeted oral prophylactic therapy for patients with HAE aged 2 and older, and one abstract featuring clinical trial outcomes http://www.streetinsider.com/Press+Releases/BioCryst+to+Present+New+HAE+Data+from+ORLADEYO%C2%AE+%28berotralstat%29+and+Navenibart+at+the+2026+European+Academy+of+Allergy+and+Clinical+Immunology+Annual+Meeting/26553317.html Wed, 27 May 2026 07:00:00 -0400 A.50201579 BCRX O.00165123 O.12524441 http://www.streetinsider.com/Press+Releases/BioCryst+to+Present+New+HAE+Data+from+ORLADEYO%C2%AE+%28berotralstat%29+and+Navenibart+at+the+2026+European+Academy+of+Allergy+and+Clinical+Immunology+Annual+Meeting/26553317.html <p align="justify">RESEARCH TRIANGLE PARK, N.C., May 27, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=rWjnYBZ0NEv6PV8MV_OqzZbCyf-t1cv1dpK0IGNVXzVwSpJslKzI8yNpkg-ckrtUAVApCIMobIE0oXi1Y6IBIWWY2uGejegxXq-da3CVED5HycqD-IvNIIZ1DQm04P09" rel="nofollow" target="_blank">BioCryst Pharmaceuticals, Inc.</a> (Nasdaq: BCRX) today announced that the company will present seven abstracts from its hereditary angioedema (HAE) portfolio at the Annual Meeting of the European Academy of Allergy and Clinical Immunology (EAACI) taking place in Istanbul, Turkey, from June 12-15, 2026.</p> <p align="justify">Data include six abstracts featuring new clinical trial and real-world outcomes with ORLADEYO® (berotralstat), the first and only targeted oral prophylactic therapy for patients with HAE aged 2 and older, and one abstract featuring clinical trial outcomes http://www.streetinsider.com/Press+Releases/BioCryst+to+Present+New+HAE+Data+from+ORLADEYO%C2%AE+%28berotralstat%29+and+Navenibart+at+the+2026+European+Academy+of+Allergy+and+Clinical+Immunology+Annual+Meeting/26553317.html Wed, 27 May 2026 07:00:00 -0400 A.50201579 BCRX O.00165123 O.12524441 http://www.streetinsider.com/Globe+Newswire/BioCryst+to+Present+New+HAE+Data+from+ORLADEYO%C2%AE+%28berotralstat%29+and+Navenibart+at+the+2026+European+Academy+of+Allergy+and+Clinical+Immunology+Annual+Meeting/26553317.html <p align="justify">RESEARCH TRIANGLE PARK, N.C., May 27, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=rWjnYBZ0NEv6PV8MV_OqzZbCyf-t1cv1dpK0IGNVXzVwSpJslKzI8yNpkg-ckrtUAVApCIMobIE0oXi1Y6IBIWWY2uGejegxXq-da3CVED5HycqD-IvNIIZ1DQm04P09" rel="nofollow" target="_blank">BioCryst Pharmaceuticals, Inc.</a> (Nasdaq: BCRX) today announced that the company will present seven abstracts from its hereditary angioedema (HAE) portfolio at the Annual Meeting of the European Academy of Allergy and Clinical Immunology (EAACI) taking place in Istanbul, Turkey, from June 12-15, 2026.</p> <p align="justify">Data include six abstracts featuring new clinical trial and real-world outcomes with ORLADEYO® (berotralstat), the first and only targeted oral prophylactic therapy for patients with HAE aged 2 and older, and one abstract featuring clinical trial outcomes http://www.streetinsider.com/Globe+Newswire/BioCryst+to+Present+New+HAE+Data+from+ORLADEYO%C2%AE+%28berotralstat%29+and+Navenibart+at+the+2026+European+Academy+of+Allergy+and+Clinical+Immunology+Annual+Meeting/26553317.html Wed, 27 May 2026 07:00:00 -0400 A.50201579 BCRX O.00165123 O.12524441 http://www.streetinsider.com/Globe+Newswire/BioCryst+to+Present+New+HAE+Data+from+ORLADEYO%C2%AE+%28berotralstat%29+and+Navenibart+at+the+2026+European+Academy+of+Allergy+and+Clinical+Immunology+Annual+Meeting/26553317.html <p align="justify">RESEARCH TRIANGLE PARK, N.C., May 27, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=rWjnYBZ0NEv6PV8MV_OqzZbCyf-t1cv1dpK0IGNVXzVwSpJslKzI8yNpkg-ckrtUAVApCIMobIE0oXi1Y6IBIWWY2uGejegxXq-da3CVED5HycqD-IvNIIZ1DQm04P09" rel="nofollow" target="_blank">BioCryst Pharmaceuticals, Inc.</a> (Nasdaq: BCRX) today announced that the company will present seven abstracts from its hereditary angioedema (HAE) portfolio at the Annual Meeting of the European Academy of Allergy and Clinical Immunology (EAACI) taking place in Istanbul, Turkey, from June 12-15, 2026.</p> <p align="justify">Data include six abstracts featuring new clinical trial and real-world outcomes with ORLADEYO® (berotralstat), the first and only targeted oral prophylactic therapy for patients with HAE aged 2 and older, and one abstract featuring clinical trial outcomes http://www.streetinsider.com/Globe+Newswire/BioCryst+to+Present+New+HAE+Data+from+ORLADEYO%C2%AE+%28berotralstat%29+and+Navenibart+at+the+2026+European+Academy+of+Allergy+and+Clinical+Immunology+Annual+Meeting/26553317.html Wed, 27 May 2026 07:00:00 -0400 A.50201579 BCRX O.00165123 O.12524441 http://www.streetinsider.com/Globe+Newswire/BioCryst+to+Present+New+HAE+Data+from+ORLADEYO%C2%AE+%28berotralstat%29+and+Navenibart+at+the+2026+European+Academy+of+Allergy+and+Clinical+Immunology+Annual+Meeting/26553317.html <p align="justify">RESEARCH TRIANGLE PARK, N.C., May 27, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=rWjnYBZ0NEv6PV8MV_OqzZbCyf-t1cv1dpK0IGNVXzVwSpJslKzI8yNpkg-ckrtUAVApCIMobIE0oXi1Y6IBIWWY2uGejegxXq-da3CVED5HycqD-IvNIIZ1DQm04P09" rel="nofollow" target="_blank">BioCryst Pharmaceuticals, Inc.</a> (Nasdaq: BCRX) today announced that the company will present seven abstracts from its hereditary angioedema (HAE) portfolio at the Annual Meeting of the European Academy of Allergy and Clinical Immunology (EAACI) taking place in Istanbul, Turkey, from June 12-15, 2026.</p> <p align="justify">Data include six abstracts featuring new clinical trial and real-world outcomes with ORLADEYO® (berotralstat), the first and only targeted oral prophylactic therapy for patients with HAE aged 2 and older, and one abstract featuring clinical trial outcomes http://www.streetinsider.com/Globe+Newswire/BioCryst+to+Present+New+HAE+Data+from+ORLADEYO%C2%AE+%28berotralstat%29+and+Navenibart+at+the+2026+European+Academy+of+Allergy+and+Clinical+Immunology+Annual+Meeting/26553317.html Wed, 27 May 2026 07:00:00 -0400 A.50201579 BCRX O.00165123 O.12524441 http://www.streetinsider.com/Globe+Newswire/BioCryst+to+Present+New+HAE+Data+from+ORLADEYO%C2%AE+%28berotralstat%29+and+Navenibart+at+the+2026+European+Academy+of+Allergy+and+Clinical+Immunology+Annual+Meeting/26553317.html <p align="justify">RESEARCH TRIANGLE PARK, N.C., May 27, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=rWjnYBZ0NEv6PV8MV_OqzZbCyf-t1cv1dpK0IGNVXzVwSpJslKzI8yNpkg-ckrtUAVApCIMobIE0oXi1Y6IBIWWY2uGejegxXq-da3CVED5HycqD-IvNIIZ1DQm04P09" rel="nofollow" target="_blank">BioCryst Pharmaceuticals, Inc.</a> (Nasdaq: BCRX) today announced that the company will present seven abstracts from its hereditary angioedema (HAE) portfolio at the Annual Meeting of the European Academy of Allergy and Clinical Immunology (EAACI) taking place in Istanbul, Turkey, from June 12-15, 2026.</p> <p align="justify">Data include six abstracts featuring new clinical trial and real-world outcomes with ORLADEYO® (berotralstat), the first and only targeted oral prophylactic therapy for patients with HAE aged 2 and older, and one abstract featuring clinical trial outcomes http://www.streetinsider.com/Globe+Newswire/BioCryst+to+Present+New+HAE+Data+from+ORLADEYO%C2%AE+%28berotralstat%29+and+Navenibart+at+the+2026+European+Academy+of+Allergy+and+Clinical+Immunology+Annual+Meeting/26553317.html Wed, 27 May 2026 07:00:00 -0400 A.50201579 BCRX O.00165123 O.12524441 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BIOCRYST+PHARMACEUTICALS++For%3A+May+18++Filed+by%3A+McKee+Amy+E/26521138.html si-local-file:///var/storage/secattach/20260519/26521138.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BIOCRYST+PHARMACEUTICALS++For%3A+May+18++Filed+by%3A+McKee+Amy+E/26521138.html Tue, 19 May 2026 16:07:00 -0400 BCRX O.00165123 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BIOCRYST+PHARMACEUTICALS++For%3A+May+18++Filed+by%3A+McKee+Amy+E/26521138.html si-local-file:///var/storage/secattach/20260519/26521138.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BIOCRYST+PHARMACEUTICALS++For%3A+May+18++Filed+by%3A+McKee+Amy+E/26521138.html Tue, 19 May 2026 16:07:00 -0400 BCRX O.00165123 http://www.streetinsider.com/SEC+Filings/Form++144++++++++BIOCRYST+PHARMACEUTICALS+++++++++++++++Filed+by%3A+McKee+Amy+E/26514699.html si-local-file:///var/storage/secattach/20260518/26514699.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++BIOCRYST+PHARMACEUTICALS+++++++++++++++Filed+by%3A+McKee+Amy+E/26514699.html Mon, 18 May 2026 16:48:00 -0400 BCRX O.00165123 http://www.streetinsider.com/SEC+Filings/Form++144++++++++BIOCRYST+PHARMACEUTICALS+++++++++++++++Filed+by%3A+McKee+Amy+E/26514699.html si-local-file:///var/storage/secattach/20260518/26514699.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++BIOCRYST+PHARMACEUTICALS+++++++++++++++Filed+by%3A+McKee+Amy+E/26514699.html Mon, 18 May 2026 16:48:00 -0400 BCRX O.00165123 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BIOCRYST+PHARMACEUTICALS++For%3A+May+13++Filed+by%3A+Barnes+Alane+P/26505338.html si-local-file:///var/storage/secattach/20260515/26505338.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BIOCRYST+PHARMACEUTICALS++For%3A+May+13++Filed+by%3A+Barnes+Alane+P/26505338.html Fri, 15 May 2026 16:13:00 -0400 BCRX O.00165123 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BIOCRYST+PHARMACEUTICALS++For%3A+May+13++Filed+by%3A+Barnes+Alane+P/26505338.html si-local-file:///var/storage/secattach/20260515/26505338.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BIOCRYST+PHARMACEUTICALS++For%3A+May+13++Filed+by%3A+Barnes+Alane+P/26505338.html Fri, 15 May 2026 16:13:00 -0400 BCRX O.00165123 http://www.streetinsider.com/SEC+Filings/Form++144++++++++BIOCRYST+PHARMACEUTICALS+++++++++++++++Filed+by%3A+Barnes+Alane+P/26484691.html si-local-file:///var/storage/secattach/20260513/26484691.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++BIOCRYST+PHARMACEUTICALS+++++++++++++++Filed+by%3A+Barnes+Alane+P/26484691.html Wed, 13 May 2026 13:06:00 -0400 BCRX O.00165123